Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.48 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.48 |
| ▸ | PDE1A | P54750 | 5/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494831 | 0.93 | PDE4B (0.57) | PDE4BPDE1BPDE1CPDE1APDE3B | |
| SCHEMBL4339793 | 0.82 | PDE4B (0.51) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL4952531 | 0.81 | PDE4B (0.42) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL4931199 | 0.80 | PDE4B (0.43) | PDE4B | |
| SCHEMBL4954967 | 0.77 | PDE1B (0.42) | PDE1BPDE1CPDE1A | |
| SCHEMBL4952368 | 0.77 | PDE1B (0.42) | PDE1BPDE1CPDE1A | |
| SCHEMBL4934686 | 0.77 | PDE4B (0.44) | PDE4B | |
| SCHEMBL4954908 | 0.77 | PDE4B (0.39) | PDE4B | |
| SCHEMBL4935591 | 0.76 | PDE4B (0.57) | PDE4B | |
| SCHEMBL8341759 | 0.76 | PDE4B (0.60) | PDE4BPDE3BPDE7APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | PDE4B 4/4885PDE1B 210/4885PDE1C 203/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | PDE4B 4/4885PDE1B 210/4885PDE1C 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.